Related Experiment Video
Updated: Jun 12, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Clinical experience with adalimumab in the treatment of ocular Behçet disease
Ahmed Bawazeer1, Lina H Raffa, S H M Nizamuddin
1King Abdulaziz University Hospital, Jeddah, Saudi Arabia. drbawazeer@yahoo.com
Purpose:
To describe the clinical outcome of refractory ocular Behçet disease with adalimumab therapy.
Method:
Retrospective review of records.
Results:
Twenty-one eyes of 11 male patients with ocular Behçet disease received adalimumab therapy. Of the 21 eyes, 17 had improvement of visual acuity by more than 3 lines after the average follow-up of 10.8 months. Ten out of 11 patients showed complete resolution of inflammation by 4 weeks. The dosages of corticosteroids and immunosuppressive drugs were reduced in most of the patients and stopped altogether in 3 and 6 patients, respectively. One patient on infliximab showed improvement of inflammation after switching over to adalimumab. No serious side effects were observed in any of the patients.
Conclusion:
Adalimumab appears to be effective in Behçet disease. It has been shown to improve visual acuity and also to have a corticosteroid and immunosuppressive sparing effect. It can induce and maintain sustained remission of the disease.
Related Concept Videos
Microbiome of the Eye
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Ophthalmic Drug Delivery Systems
